Research progress of drugs for treatment of carbapenem-resistant Ente-robacterales infection in children
Author:
Affiliation:

Department of Pharmacy, Anhui Provincial Hospital, The First Affiliated Hospital of University of Science and Technology of China, Hefei 230001, China

Clc Number:

R378.2

Fund Project:

  • Article
  • |
  • Figures
  • |
  • Metrics
  • |
  • Reference
  • |
  • Related
  • |
  • Comments
    Abstract:

    In recent years, with the widely application of carbapenems, carbapenem-resistant Enterobacterales (CRE) infection is increasingly prevalent in children, and are often associated with poor clinical outcomes. Due to the specific pharmacokinetic/pharmacodynamic (PK/PD) characteristics of children, most anti-CRE antimicrobial agents lack clinical application experience in children, and pediatricians face huge challenge in the treatment of CRE. In this paper, the existing knowledge of CRE infection in children is collected, epidemiology, antimicrobial resis-tance mechanisms and the latest treatment strategies are reviewed, so as to provide a reference for clinical medication.

    Reference
    Related
Get Citation

周冉,方玉婷,苏丹,等.儿童耐碳青霉烯类肠杆菌目细菌感染治疗药物研究进展[J].中国感染控制杂志英文版,2022,(2):204-208. DOI:10.12138/j. issn.1671-9638.20226649.
Ran ZHOU, Yu-ting FANG, Dan SU, et al. Research progress of drugs for treatment of carbapenem-resistant Ente-robacterales infection in children[J]. Chin J Infect Control, 2022,(2):204-208. DOI:10.12138/j. issn.1671-9638.20226649.

Copy
Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:March 11,2021
  • Revised:
  • Adopted:
  • Online: April 28,2024
  • Published: